Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of AZD5718 Formulations
NCT04210388Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atuliflapon in coronary artery disease (CAD) (5 arms), sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity, Area under the plasma concentration-curve from time zero to time of last quantifiable concentration and 4 more. Started Jan 2020; status: completed.
02
Drugs
atuliflapon
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04210388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210388.